Biotech
NUVA BUYBUY signal at 65.73$.
Timeframe - 1 week.
Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
If you want to see more history of this strategy, I able to show you if you request me.
It's one of two signal algo for NUVA.
ATTENTION this strategy may has downtrend about 10-15%, so you can split your buy order, that you have not big downtrend.
__________________________________________________________________________
You can use the signals independently or like indicator of trends together with other indicators in your trading strategy.
Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies.
You use these signals inside your strategies at your own risk.
The chart shows the last trades on the product + the last signal.
I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile.
Therefore, subscribe and watch for that profile.
The signals rare but useful.
Harmonic ButterflyMRKR showing signs of life after testing a key Fibonacci level of support.
Chart:
Double bottom
CCI moved positive (inferring a nice loading zone)
MS Signal is showing "Over-Sold" conditions
Key *Support needs to hold $3.80
Key *Resistance at $4.53 then $5.29 (highlighted in green shaded area)
Disclosure: I do not own MRKR. I may buy/ sell within the next 72 hours. This is not a recommendation to buy or sell. Please do your homework before investing.
Can TTNP Actually Gap Fill Or Is It Forever Going To Trade Here?TTNP has been catching attention on volume scans this month. Ever since gapping down on October 16, the daily action is noticeably greater than before. But is this a good or bad sign for the penny stock? Currently trading around $0.20. OS is around 17 million so it's not the biggest out there but not the smallest either.
Titan Pharmaceuticals is a company that develops treatments for chronic diseases using its ProNeura platform. Titan announced a $9 million public offering a week ago. While the company’s stock took a price hit due to the per-share pricing of the offering it is okay.It is okay because ever since the company did this, a surge of volume has entered the stock. In addition to this, analysts are taking notice of the company too. Maxim Group upgraded TTNP stock from “HOLD” to “BUY” this week and gave a $1 price target.
ABOUT TTNP
Titan Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development of pharmaceutical products. Its product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson's disease, Triiodothyronine (T3) for hypothyroidism. It generates revenue principally from collaborative research and development arrangements, technology licenses, and government grants.
QUOTE SOURCE: 4 Penny Stocks Catching Biotech Investors By Surprise
$SGEN Shorterm BearishHello Traders!
It looks like $SGEN has made a local top and will be headed for consolidation. Not to worry, I believe continued upside potential is favored. My plan includes stacking buy orders at $90-$75 with stops at $70. Do your own DD, and good luck!
Yo boy,
Pic
Abbvie brakes 200SMA ABBV is currently breaking the 200sma, ending a 14 month downtrend.
On the next days I will be tracking the next tools:
OBV should trend higher to confirm this new uptrend. It still has not done that.
3 candlestick closes above the 200SMA would also be a confirmation signal.
BIOT LongGood Entry for a little swing
Biot tripple bottomed and tripple bullish divergence on the RSI.
Trading inside a descending wedge for the last couple of weeks that signals that price action sending the price north is due .
Gartley + Additional data release todayFriday, October 11, 2019
ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the Retina Sub-specialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA.
NEXT EARNING: Nov 11, 2019
MARKET CAP: $333.254 Million
Technical Analysis:
-Bullish Gartley pattern
-Fibonacci 876 retracement is an important reversal level in high volatility trades.
-Our MS Signal oscillator indicating RSI moving higher and now being a potential good time to buy for a bounce.
-MS CCI Squeeze also indicating that bulls are re-gaining control (over mid-line suggests potential squeeze incoming)
Please like, share, and follow so I can continue finding awesome trades. Check out MS Money Trade Ideas for pre-researched trades to add to your watchlist!! Thanks in advance.
Disclosure: I am long ADVM. I may buy or sell within the next 72 hours. This is not a recommendation to buy or sell. Please do your homework before investing.
ADIL10:09 AM EDT, 09/11/2019 (MT Newswires) -- Adial Pharmaceuticals (ADIL) said Wednesday that it has successfully retested a previously manufactured supply of clinical trial packaged tablets of the investigational drug AD04 for the treatment of alcohol use disorder.
The company said tests showed that the clinical trial materials passed reevaluation and are eligible for use in the phase 3 trial.
The company has great information about it on their website with promising statisics.
$OVID Holding The Gap But Can it Sustain?One thing to look at especially when it comes to penny stocks is volume. If you look at this chart, OVID stock is holding above the previous gap zone. However, volume has consistently deteriorated. My question is can this sustain levels above the gap zone or are we looking at a further pullback?
" Since June, shares of this biotechnology penny stock rallied from lows of $1.53 to highs of $3.97 late last month. However, on Friday, the stock tanked 27% after announcing a public offering to raise money for the company.Even so, the proceeds of the gross $32.5 million will be put to immediate use. Proceeds from the Offerings will be used “primarily to advance the clinical development of its OV101 and OV935 programs.” The remainder will be for working capital and general corporate purposes. " *
About OVID
Ovid Therapeutics Inc is a US based biopharmaceutical company. The firm is engaged primarily in developing impactful medicines for patients and families living who are suffering with rare neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life.
* Quote Source: 3 Penny Stocks To Watch After Latest Biotech News
$ZIOPZiopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors to target neoantigens inside and outside hotspots for solid tumors and CAR to target CD19 for blood cancers using the Company’s rapid personalized manufacturing to produce and release CAR-T within two days of gene transfer. The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Build Positions in BiotechAs the month of October begins and broader markets sold off, Biotech sectors are still negative/ flat for the year. Market headlines from high prescription drug prices and lawsuits regarding the opioid epidemic have plagued some of the IBB's largest holdings; which have held biotech ETF's down while the S&P reached all time highs.
Fast-Track Synopsis:
Biotech is a known high volatility trading environment;
More Investors will become "Traders" with new $0 trading fee platforms from Schwab and TD Ameritrade.
Once people begin trading stocks, they will find that high volatility is how the "big" day-trade/ swing trading money is made.
New Med-tech and Biotechnology therapies (i.e. gene therapies, NASH/ NAFLD) are ripening and getting closer to approval.
There are currently over 240 biotechnology companies with Gene therapy IP
IP has been growing with RMAT and Breakthrough Designations due to unmet need of new novel treatments;
As Biotech rolls into year-end, lower interest rates will propel company growth models which I believe will help drive buy outs.
LABU Technical Analysis:
Bullish Harmonic Gartley pattern and close to 52-week low.
1-year Gartley pattern should move LABU stock price back up to around $40 level (resistance) where we will be watching for a potential breakout
CCI measured "oversold" with the end of September pullback, CCI-slope is now trending higher,
This last pullback also measures a double bottom (data points are from Christmas 2018 and present)
Intra-day bullish RSI divergence, Daily RSI trending higher;
the MS Signal recently flipped green as of 10/1/2019 and is still indicating a nice swing opportunity to come.
Three-drives pattern bouncing toward resistance concurrent with double bottom and Gartley pattern.
Look for the support level (marked (x)) to hold.
See conclusion here !
Please like and follow so we can continue finding awesome charts/ trades. For more pre-researched Biotech trade-ideas click and visit us at MS Money Moves . Thanks in advance everyone!!
Disclosure: I do not own LABU, I may buy or sell within the next 48 hours. This is not a recommendation to buy or sell. Please do your homework before investing.
$LXRX Fill The Gap And Go Or Will It Breakdown?LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week?
"Shares of LXRX stock have been on a tear for around a month. This was ever since terminating its partnership agreement with Sanofi. The termination gave Lexicon full control over its diabetes product Zynquista and in addition to that, Sanofi is going to pay the company as much as $260 million as a parting shot...The company will be conducting poster presentations of its XERMELO therapy this week at the North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium." *
About LXRX
Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.
*SOURCE: Are Penny Stocks Worth It? 3 Up Big In October
